BioCentury | Feb 2, 2021
Finance

Prophylactic antibacterials backed by CARB-X: Data Byte

...and CDC.Nine of those awards went to companies developing prophylactics, the most recent awardee being Lumen Bioscience Inc....
BioCentury | Jan 23, 2021
Emerging Company Profile

Technology showcase: BioCentury’s 2020 class of emerging companies

...solely on lowering manufacturing costs and streamlining processes. Lumen Bioscience Inc....
BioCentury | Sep 12, 2020
Management Tracks

New CEO Hirsch to guide C4 onto NASDAQ; plus Biller adds CFO title at Agios and updates from Sherlock, Lumen and more

...Inc. and Emulate Inc.After raising $16 million in a series B round last week, biologics manufacturer Lumen Bioscience Inc....
BioCentury | Sep 4, 2020
Emerging Company Profile

Lumen growing lean, green biologics with $16M series B and Gates funding

...Melinda Gates Foundation. CEO Brian Finrow told BioCentury Lumen Bioscience Inc.’s...
BioCentury | Aug 16, 2019
Emerging Company Profile

A-Alpha Bio retools yeast mating for high throughput drug discovery

A-Alpha Bio is co-opting yeast mating to scale up screening of candidates that create or block protein-protein interactions. The University of Washington spinout is partnering with drug developers to find biologics with defined specificity profiles,...
Items per page:
1 - 5 of 5
BioCentury | Feb 2, 2021
Finance

Prophylactic antibacterials backed by CARB-X: Data Byte

...and CDC.Nine of those awards went to companies developing prophylactics, the most recent awardee being Lumen Bioscience Inc....
BioCentury | Jan 23, 2021
Emerging Company Profile

Technology showcase: BioCentury’s 2020 class of emerging companies

...solely on lowering manufacturing costs and streamlining processes. Lumen Bioscience Inc....
BioCentury | Sep 12, 2020
Management Tracks

New CEO Hirsch to guide C4 onto NASDAQ; plus Biller adds CFO title at Agios and updates from Sherlock, Lumen and more

...Inc. and Emulate Inc.After raising $16 million in a series B round last week, biologics manufacturer Lumen Bioscience Inc....
BioCentury | Sep 4, 2020
Emerging Company Profile

Lumen growing lean, green biologics with $16M series B and Gates funding

...Melinda Gates Foundation. CEO Brian Finrow told BioCentury Lumen Bioscience Inc.’s...
BioCentury | Aug 16, 2019
Emerging Company Profile

A-Alpha Bio retools yeast mating for high throughput drug discovery

A-Alpha Bio is co-opting yeast mating to scale up screening of candidates that create or block protein-protein interactions. The University of Washington spinout is partnering with drug developers to find biologics with defined specificity profiles,...
Items per page:
1 - 5 of 5